- Home
- TERN vs ESPR Comparison
TERN vs ESPR Comparison
Compare TERN & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TERN
- ESPR
- Stock Information
- Founded
- TERN 2017
- ESPR 2008
- Country
- TERN United States
- ESPR United States
- Employees
- TERN N/A
- ESPR N/A
- Industry
- TERN Biotechnology: Pharmaceutical Preparations
- ESPR Biotechnology: Pharmaceutical Preparations
- Sector
- TERN Health Care
- ESPR Health Care
- Exchange
- TERN Nasdaq
- ESPR Nasdaq
- Market Cap
- TERN 710.6M
- ESPR 660.1M
- IPO Year
- TERN 2021
- ESPR 2013
- Fundamental
- Price
- TERN $20.33
- ESPR $3.13
- Analyst Decision
- TERN Buy
- ESPR Buy
- Analyst Count
- TERN 11
- ESPR 6
- Target Price
- TERN $21.19
- ESPR $6.50
- AVG Volume (30 Days)
- TERN 4.5M
- ESPR 5.9M
- Earning Date
- TERN 11-10-2025
- ESPR 11-06-2025
- Dividend Yield
- TERN N/A
- ESPR N/A
- EPS Growth
- TERN N/A
- ESPR N/A
- EPS
- TERN N/A
- ESPR N/A
- Revenue
- TERN N/A
- ESPR $303,802,000.00
- Revenue This Year
- TERN N/A
- ESPR $18.83
- Revenue Next Year
- TERN N/A
- ESPR N/A
- P/E Ratio
- TERN N/A
- ESPR N/A
- Revenue Growth
- TERN N/A
- ESPR 2.83
- 52 Week Low
- TERN $1.87
- ESPR $0.69
- 52 Week High
- TERN $21.12
- ESPR $3.94
- Technical
- Relative Strength Index (RSI)
- TERN 80.52
- ESPR 59.41
- Support Level
- TERN $7.87
- ESPR $2.42
- Resistance Level
- TERN $21.74
- ESPR $2.99
- Average True Range (ATR)
- TERN 1.46
- ESPR 0.21
- MACD
- TERN 1.11
- ESPR 0.01
- Stochastic Oscillator
- TERN 90.25
- ESPR 81.04
About TERN Terns Pharmaceuticals Inc.
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases. Its product candidates include TERN-701, TERN-601, TERN-501 and TERN-800.
About ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.